Jonathan Lim

Everyone is trying to save time and money in health care these days, and Halozyme Therapeutics is attempting to provide some solutions.

The company is working on treatments for cancer and diabetes, based around certain enzymes. It has two products in Phase III development, one product in Phase II and two in earlier stages of development. Three of these products are treatments that take drugs currently administered intravenously in a clinic, and make it possible to inject them through the skin at home.

“As health care costs escalate, any new technologies that can help manage those costs would be of tremendous benefit,” said Jonathan Lim, former president and chief executive officer.

Lim stepped down in early December. He had been with Halozyme (Nasdaq: HALO) since 2003, hired as only its fifth employee. During his tenure, the company has experienced a 3,000 percent return on investment.